Primary breast cancer
Conditions
Interventions
The test group:None
The control group:None
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 18~70 years old; 2. Patients with primary breast cancer confirmed by pathology by fine needle or core needle aspiration biopsy. Have a clear measurable tumor lesion, the length and diameter of the lesion > 10 mm; 3. Have a complete general examination, excluding distant metastasis of tumors; 4. Systemic functional status PS (ECOG) score=10.0 g/dl, neutrophil count >=1.5×10^9/L, platelet count >=90×10^9/L; Blood biochemistry: serum total bilirubin =50%); 7. Not receiving anti-tumor chemoradiotherapy or endocrine therapy before neoadjuvant therapy; 8. Patients with occult breast cancer, which must be confirmed by pathology, and axillary lymph nodes can be used as measurable lesions; 9. Completed neoadjuvant therapy and surgical treatment, and have retained plasma samples before neoadjuvant therapy, after the second cycle of neoadjuvant therapy and three time points before surgery; 10. Previously signed consent form for neoadjuvant therapy and informed consent form for retained plasma specimens for clinical research.
Exclusion criteria
Exclusion criteria: 1.Neoadjuvant therapy or surgical treatment has not been completed; 2.Combined with other malignant tumors at the same time, except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix; 3.The patient is accompanied by uncontrolled heart, lung and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases and other diseases; 4.Chemotherapy, radiotherapy and endocrine therapy have been received before neoadjuvant therapy; 5.Patients during lactation and pregnancy; 6.Plasma samples were not retained during neoadjuvant therapy; 7.No previously signed consent form for neoadjuvant therapy and/or informed consent form for retention of plasma specimens for clinical research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinicopathological characteristics;Pathological complete response,pCR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Distant disease free survival(DDFS);Disease-free survival time(DFS); | — |
Countries
China
Contacts
Public ContactLigang Niu
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed